Since CD133 expression seems to be related to chemoresistance [116], the ability of metformin to preferentially target CD133+ cells highlights the possibility that this drug could overcome pharmacological resistance in GBM or in other sensitive tumors. This evidence concerns the gene PROM1 and glioblastoma.